Document is current
Any future updates will be listed below
-
Authors
Lu, I-Na https://orcid.org/0000-0002-3845-7386
Cheung, Phyllis Fung-Yi
Heming, Michael https://orcid.org/0000-0002-9568-2790
Thomas, Christian https://orcid.org/0000-0002-6642-7774
Giglio, Giovanni https://orcid.org/0009-0009-0349-3756
Leo, Markus
Erdemir, Merve
Wirth, Timo https://orcid.org/0000-0002-0102-4608
König, Simone
Dambietz, Christine A.
Schroeter, Christina B. https://orcid.org/0000-0002-1391-7817
Nelke, Christopher
Siveke, Jens T. https://orcid.org/0000-0002-8772-4778
Ruck, Tobias https://orcid.org/0000-0001-6332-8650
Klotz, Luisa https://orcid.org/0000-0001-5439-9633
Haider, Carmen
Höftberger, Romana
Kleinschnitz, Christoph
Wiendl, Heinz https://orcid.org/0000-0003-4310-3432
Hagenacker, Tim https://orcid.org/0000-0002-3631-3450
Meyer zu Horste, Gerd https://orcid.org/0000-0002-4341-4719
- License Information
-
More Information
Article History
Received: 15 June 2023
Accepted: 24 April 2024
First Online: 15 May 2024
Competing interests
: G.M.z.H. received compensation for serving on scientific advisory boards (LFB, Roche, Immunovant) and speaker honoraria (Alexion, LFB, Argenx). H.W. is acting as a paid consultant for AbbVie, Actelion, Biogen, IGES, Johnson & Johnson, Novartis, Roche, Sanofi-Aventis and the Swiss Multiple Sclerosis Society. C.K. received lecture and consultancy fees from Biogen, Roche and Novartis. T.H. received lecture and consultancy fees from Biogen, Roche and Novartis, as well as research support from Biogen, Roche and Novartis Gene Therapies. The remaining authors declare no competing interests.
